| アブストラクト | Despite nationwide cohort studies revealing an increased risk of malignant melanoma (MM) in people with multiple sclerosis (PwMS), the connection between MS disease-modifying therapies (DMTs) and MM risk remains underexplored. We identified 1200 reports of MM associated with MS DMTs in the FDA Adverse Event Reporting System (FAERS), and a pooled analysis of all DMTs showed disproportionately high MM reporting compared to all other FAERS medications (reporting odds ratio, 2.30; 95% confidence interval, 2.16-2.45; chi(2), 702.33). As MS DMTs may influence MM risk, clinicians should educate PwMS on the importance of regular skin self-examinations. |
|---|
| ジャーナル名 | Multiple sclerosis (Houndmills, Basingstoke, England) |
|---|
| Pubmed追加日 | 2025/6/26 |
|---|
| 投稿者 | Balshi, Alexandra; Dempsey, John P; Manning, Nova; Leuenberger, Grace; Baber, Ursela; Sloane, Jacob A |
|---|
| 組織名 | Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical;School, Boston, MA, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40566642/ |
|---|
